BMJ Open

Prospective open-label non-inferiority randomised controlled trial comparing letrozole and mifepristone pretreatment in medical management of first trimester missed miscarriage: study protocol

Libei Du,1 Raymond Hang Wun Li,1,2 Kristina Gemzell-Danielsson,1,2,3 Yan Hong Du,1 Li Zhang,1 Wei Yu Diao,1 Pak Chung Ho1,2

ABSTRACT

Introduction  Medical treatment is a less invasive alternative to surgical management of missed miscarriage. Studies have shown that pretreatment with mifepristone can increase the complete abortion rate in management of first-trimester missed miscarriage compared with misoprostol alone. Two studies have also shown that pretreatment with letrozole could increase the efficacy compared with misoprostol alone. So far, there is no trial comparing letrozole and mifepristone pretreatment for missed miscarriage. We designed this randomised controlled trial to test the hypothesis that for first-trimester missed miscarriage, letrozole pretreatment is non-inferior to mifepristone pretreatment followed by misoprostol in terms of complete abortion rate.

Methods and analysis  This is a prospective open-label non-inferiority randomised controlled trial conducted in a single centre. In total, 294 women diagnosed with first-trimester missed miscarriage opting for medical treatment is recruited with informed consent. They are randomly assigned to receive mifepristone or letrozole pretreatment. In the mifepristone group, each woman takes 200 mg mifepristone orally followed 24–48 hours later by 800 µg misoprostol vaginally. In the letrozole group, each woman takes 10 mg letrozole orally per day for 3 days, followed by 800 µg misoprostol vaginally on the third day of letrozole administration. Follow-up is conducted on days 15 and 42 after misoprostol administration. The primary outcome is the overall complete abortion rate. Secondary outcomes include side effects and complications during the study period. Data will be analysed with both intention-to-treat and per protocol approaches. A p<0.05 will be considered as indicating statistical significance.

Ethics and dissemination  Ethics approval has been obtained from the Institutional Review Board of the University of Hong Kong-Shenzhen Hospital with approval number: (2020)166. Findings will be disseminated in a peer-reviewed journal and in national and/or international meetings to guide future practice.

Trial registration number  ChiCTR2000041480.

INTRODUCTION

Missed miscarriage is a common early pregnancy complication that occurs in 15%–20% of all clinical pregnancies, and the majority of miscarriages occur in the first trimester.1 2 Missed miscarriage and incomplete miscarriage are two main types of miscarriages that require medical intervention. Missed miscarriage is diagnosed when a non-viable pregnancy or anembryonic pregnancy is identified on ultrasound scan without associated pain or bleeding, which is also known as delayed or silent miscarriage or missed abortion.3 Incomplete miscarriage is diagnosed when pregnancy tissue has been partly expelled by the uterus.4 The treatment options for early pregnancy loss include expectant management, medical management and surgical evacuation.5 Surgical evacuation is a quick procedure with high success rate, but it is associated with risks of mechanical injury and postoperative intrauterine adhesions which may affect future fertility.6 Medical treatment of miscarriage is safe and less costly than surgical evacuation, and can avoid the surgical complications. Disadvantages of medical management include longer
duration of bleeding and higher risk of unplanned surgical procedures such as curettage.\textsuperscript{7,8} Compared with expectant management, it shortens the time-to-abortion in a non-invasive manner, which may lessen the psychological burden to some women.\textsuperscript{9,10} Misoprostol induces uterine myometrial contractions as well as cervical softening and dilation. It is widely used to induce abortion either alone or following pretreatment with mifepristone. Vaginal misoprostol was recommended for medical treatment of missed miscarriage by the clinical guideline of the National Institute for Health and Care Excellence (NICE), UK.\textsuperscript{11} Treatment with repeat doses of misoprostol is effective, safe and acceptable. When used alone for medical management of miscarriage, the standard dose of misoprostol is 800 µg vaginally or 600 µg sublingually.\textsuperscript{12} It may work less well in women with a closed cervix. Up to 15\%–40\% of women with missed miscarriage need a second dose of misoprostol or eventually need surgical evacuation due to failed or incomplete abortion.\textsuperscript{12,15} Mifepristone pretreatment has been shown to increase the success rate. The reported complete abortion rate of pretreatment with mifepristone followed by misoprostol for the medical management of first trimester missed miscarriage in previous clinical trials has ranged from 79\% to 87\%, and that of misoprostol alone ranged from 58\% to 76\%.\textsuperscript{17-23} As access to mifepristone is restricted in some countries, and some patients may have contraindications to the use of mifepristone, it is important to find a replacement for mifepristone for medical treatment of missed miscarriage.\textsuperscript{24} We propose that letrozole may be a good alternative. Letrozole is an oral aromatase inhibitor,\textsuperscript{25} which can inhibit oestrogen synthesis. It has been shown to be useful when combined with misoprostol in medical abortion as a possible alternative to mifepristone.\textsuperscript{26} A pilot study showed that a combination of letrozole and misoprostol used for termination of pregnancy up to 63 days achieved a complete abortion rate of 95\%.\textsuperscript{27} Another pilot study showed that combination of letrozole, mifepristone and misoprostol used for terminations of pregnancy up to 63 days achieved a complete abortion rate of 98\%.\textsuperscript{28} A randomised controlled trial (RCT) has reported that pretreatment with letrozole followed by misoprostol can improve the complete abortion rate and reduce the interval between induction and abortion for first trimester miscarriage. This study showed a complete abortion rate of 78\% in the letrozole pretreatment group and 39\% in the placebo group. The interval between induction and abortion in the letrozole group was 1.42 days which was shorter than that in the placebo group (3.09 days).\textsuperscript{29} Another RCT showed a complete abortion rate of 93.7\% in the letrozole plus misoprostol group compared with 68.7\% in the misoprostol alone group for the treatment of first trimester non-viable pregnancies.\textsuperscript{30}

The above randomised controlled studies suggested that pretreatment with either mifepristone or letrozole followed by misoprostol are both effective in the management of first-trimester missed miscarriage. However, so far, there is no trial comparing the effectiveness of letrozole versus mifepristone as pretreatment in this scenario. We hypothesise that medical treatment for missed miscarriage with letrozole pretreatment is non-inferior to mifepristone pretreatment followed by misoprostol. The findings of this study will guide the development of an alternative regimen for medical treatment of missed miscarriage.

**MATERIALS AND METHODS**

**Study design and setting**

This non-inferiority, open-label randomised trial is conducted at the Department of Obstetrics and Gynaecology, The University of Hong Kong–Shenzhen Hospital, Shenzhen, China. Eligible women requesting medical management of missed miscarriage who are willing to participate are recruited.

**Sample size estimation**

According to the literature, complete abortion rate with mifepristone and misoprostol is about 84\%.\textsuperscript{31} Adopting a non-inferiority margin of 6\%, a minimum sample size of 132 per group (in the ratio of 1:1) will be needed to achieve power of 80\% and type I error of 5\%. Accounting for a drop-out rate of about 10\%, a sample size of 147 in each arm, that is, 294 women in total will be recruited. We have first conducted a pilot analysis on 20 patients from each group, which revealed that the complete abortion rate in both groups were 95\% without statistically significant difference; hence no change in the sample size is needed.

**Randomisation**

Randomisation is performed when the women attend the out-patient clinic because of missed miscarriage and are about to commence medical management. Eligible women are randomly assigned to either the mifepristone or letrozole pretreatment group. The randomisation table is generated from www.sealedenvelope.com in blocks of 10. The vouchers showing the assigned arms according to the randomisation list are sealed in opaque envelopes which are opened on recruitment of each patient in sequence. Medication is administered to the patient according to the randomisation voucher by a nurse who is not involved in group allocation of the women.

**Selection of subjects**

Inclusion criteria include: (1) women aged 18 years or above who are diagnosed with first trimester missed miscarriage at 5–12 complete weeks of gestation, (2) having singleton pregnancy, (3) agreeing to participate in the trial voluntarily and (4) having no contraindications to medical abortion.

The diagnosis of missed miscarriage is made both by ultrasound scan and clinical examination. Speculum examination is performed to rule out incomplete or inevitable miscarriage. The following findings on transvaginal...
ultrasound suggests the diagnosis of missed miscarriage: crown-rump length of 7 mm or greater with no heartbeat, or mean sac diameter of 25 mm or greater with no embryo visualised in repeated ultrasound scans by two sonographers or on two occasions at least 7 days apart; absence of embryo with heartbeat 2 weeks or more after a scan that showed a gestational sac without a yolk sac; absence of embryo with heartbeat 11 days or more after a scan that showed a gestational sac with a yolk sac.3 4

Exclusion criteria include: (1) incomplete or inevitable miscarriage (defined by the clinical finding of an open cervix and bleeding), (2) suspected ectopic pregnancy, (3) history of heart, liver, kidney disease or adrenal insufficiency, (4) abnormal uterine lesions such as adenomyosis, fibroids or congenital malformations or intrauterine adhesion, (4) pregnancy with an intrauterine contraceptive device in situ, (5) history of coagulatory dysfunction or intake of anticoagulant drugs and (6) having haemoglobin level of less than 95 g/L. Informed written consent is obtained from all participants. The women can withdraw from the study for any reason at any time, and will receive the standard medical care in such case.

Treatment procedures

After obtaining written informed consent, randomisation is carried out as described above. Participants in the mifepristone group receive a single oral dose of 200 mg mifepristone at home, followed 24–48 hours later by 800 µg misoprostol administered vaginally by the nurse or the woman herself in the hospital. Based on the regimen used in a previous study on medical termination of pregnancy, patients in the letrozole group receive oral letrozole at home, 10 mg per day for three consecutive days, and on the morning of the third day they receive 800 µg of misoprostol administered vaginally in the hospital. The participants are not blinded to their allocated treatment.

After misoprostol administration, the participants shall stay in the hospital for at least 3–6 hours to observe for bleeding, tissue passage and severe adverse effects. A standard data form is used to record baseline demographics, medical history and obstetric history, timing of drug administration, side effects, timing of tissue expulsion, severity of abdominal pain and vaginal bleeding. Other side effects such as nausea, vomiting, diarrhoea, headache and fever are also recorded. Acceptability of the treatment method is assessed with the question “Will you recommend this method of treatment to someone who need the treatment?”. We are not routinely checking the rhesus status nor providing anti-D rhesus prophylaxis to women undergoing medical treatment for miscarriage. Those receiving surgical treatment who are rhesus negative will receive 250 IU anti-D immunoglobulin according to the latest NICE guideline.4 After discharge, the women are asked to record the duration of vaginal bleeding and occurrence of adverse events in the daily record charts until 42 days after misoprostol administration. The questionnaires are completed by the patients under guidance by the nurse, who are blinded to the allocation of the participants.

Participants who have no tissue passage at discharge from the hospital shall return for assessment 7 days after misoprostol use. Passage of gestational tissue, ongoing heavy vaginal bleeding and clinical signs of infection are noted. The clinician conducting the follow-up assessment is blinded to the group assigned. Women in whom the gestational sac has not been expelled by day 7 can choose to receive a second dose of 800 µg misoprostol vaginally or 400 µg misoprostol sublingually, to have expectant treatment or to undergo suction evacuation. Those who choose to have a second dose of misoprostol or expectant treatment are reviewed in another week. If the gestational sac is still not expelled 1 week after the second dose of misoprostol, suction evacuation shall be performed. All participants receive a telephone follow-up around 15 days and attend an in-person follow-up visit at 42 days after misoprostol administration to collect information about additional treatments or adverse events. In the mean time, the woman can return to the hospital if there is heavy vaginal bleeding, fever or severe abdominal pain. A pregnancy test is performed at the day 42 visit. If the result is negative, no further action is needed. If the result is positive or there is ongoing bleeding, an ultrasound scan is performed to guide further management. Complete abortion is considered if there is no gestational sac or fetal structure. Incomplete abortion is defined by a positive pregnancy test result and/or ongoing vaginal bleeding, together with sonographic finding of intrauterine material with a thickness of more than 15 mm, and either expectant or surgical treatment may be offered as per informed decision of the patient.

The study pathway is illustrated in figure 1.

Indications for suction evacuation

The indications for suction evacuation include persistent presence of a pregnancy sac 7–15 days after the first or second misoprostol administration, heavy vaginal bleeding, or incomplete abortion after 42 days following misoprostol administration. This will be an informed decision by the patient after explanation about the alternative options of expectant and repeat medical management.

Outcome measures

The primary outcome is the rate of complete abortion, defined as the complete expulsion of the gestational product without the need for suction evacuation or other intervention till follow-up at 42 days. Secondary outcomes include the rate of side effects such as nausea, vomiting, fever, severe pain, severe bleeding and other complications during the study period, as well as patient satisfaction. The need for urgent surgical intervention will also be reported.

Data analysis

Data will be analysed with both the intention-to-treat and per protocol approaches. Categorical and continuous
variables will be compared between groups by χ² test, Student’s t-test or Mann-Whitney U test as appropriate. P values of less than 0.05 will be considered as indicating statistical significance. IBM SPSS Statistics V.25 software will be used for analysing the data. The investigator performing data analysis shall be blinded to the coding of the treatment groups.

Assessment of safety
Mifepristone and misoprostol are both in wide use and are the medications recommended by the WHO for medical abortion with well documented safety profile. Letrozole has been approved by the US Food and Drug Administration with well documented safety profile.

Patient and public involvement
There is no patient and public involvement in the design and execution of this study.

Trial status
Study recruitment has been started on 28 December 2020, with 132 subjects having been recruited at the time of final revision of this manuscript.

Financing and insurance
The study is supported by internal departmental funding.

Acknowledgements
We would like to express our thanks to other doctors and nurses in the Department of Obstetrics and Gynecology who participated in patient recruitment and follow-up for this study. We would also like to thank all patients who participated in the study.

Figure 1  Flow chart of study pathway. If the pregnancy sac is not expelled by day 7, a second dose of misoprostol will be administered or surgical evacuation will be performed on day 8 as per patient’s informed choice.


